Investors

Society for Investigative Dermatology 76th Annual Meeting

Apr 26 - Apr 29, 2017

Topical Application of Self-delivering RNAi (sd-rxRNA) Compounds for Reduction of Hyperpigmentation
RXI-231: sd-rxRNA Targeting Tyrosinase (TYR)
This poster will show that reduction of tyrosinase mRNA levels by sd-rxRNA in cultured cells leads to a decrease in visible pigmentation and melanin content, in line with the expected mechanism of action of an RNAi compound. In addition, as demonstrated ex vivo in pig skin, our proprietary formulation allows for the non-invasive penetration of sd-rxRNA compounds to the epidermal dermal junction where TYR-producing melanocytes reside. Consumer testing will initiate in May 2017.
Date and Time: April 29, 2017 10:15 AM PDT
Presented by: Melissa Maxwell
Session 3: Pigmentation and Melanoma
Poster #: 810, Exhibit Hall A

Prevention of UVR Induced MMP1 Upregulation with an MMP1 Targeting Self-delivering RNAi (sd-rxRNA) Compound May Reduce the Effects of Skin Photo-aging
RXI-185: sd-rxRNA Targeting Collagenase (MMP1)
Results from a collaboration with DSM, one of the industry's leading suppliers of ingredients and innovative solutions for beauty care products, will be presented. This poster will show that RXI-185 is capable of reducing MMP1 mRNA levels and enzyme activity in cultured human dermal fibroblasts and in an in vitro human skin model after UVR-induced MMP1 upregulation. In addition, Fl-RXI-185 is capable of reducing MMP1 mRNA levels following topical administration in an ex vivo human skin model.
Date and Time: April 29, 2017 10:15 AM PDT
Presented by: Katherine Holton
Session 3: Photobiology
Poster #: 756, Exhibit Hall A

Location

Oregon Convention Center
Portland Oregon.